Dr. Kinneret Savitsky will no longer serve as Chief Executive Officer at BioLine Rx Ltd effective October 10 2016. She has held this role since January 2010. Prior to that she was General Manager of BioLine Innovations Jerusalem Ltd. since 2004. Dr. Savitsky was formerly Vice President Biology Research and Development at Compugen a biotechnology company. She joined Compugen in 1997 as Senior Scientist in Compugen newly founded laboratory and led the company shift from computational genomics to development of diagnostics and therapeutics. She was responsible for all of Compugen drug candidate identification and development as well as experimental biology. At Compugen she managed a team of over 35 scientists and drug developers
Age: 48 CEO Since 2010
972 8 642 9100 http://www.biolinerx.com
|Savitsky holds a BS degree in Biology from The Hebrew University of Jerusalem, a MS degree in Human Genetics and a Doctorate of Science degree in Human Genetics, both from TelAviv University.|
The company has return on total asset (ROA)
of (20.85) %
which means that it has lost $20.85 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE)
of (34.07) %
meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 365 K in total debt with debt to equity ratio (D/E)
of 0.01 which may suggest the company is not taking enough advantage from borrowing. BIOLINE RX LTD has Current Ratio
of 11.48 suggesting that it is liquid
and has the ability to pay its financial obligations in time and when they become due.
Filter Other Executives
BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, inlicensing, and developing therapeutic candidates that address unmet medical needs. BIOLINE RX LTD (BLNEF) is traded on OTC Market in USA. It is located in BioLineRx, Ltd.Modi?in, and employs 48 people.